{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T16:03:12Z","timestamp":1775404992891,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.pharma.2021.08.002","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T10:39:02Z","timestamp":1629455942000},"page":"169-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Topical finasteride dose evaluation for treatment of androgenetic alopecia using computer simulations"],"prefix":"10.1016","volume":"80","author":[{"given":"D.","family":"Todeschini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.C.","family":"Pedro Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dutra Duque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2021.08.002_bib0160","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0039-128X(91)90003-E","article-title":"Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5\u03b1-reductase inhibitor","volume":"56","author":"Schepper","year":"1991","journal-title":"Steroids"},{"key":"10.1016\/j.pharma.2021.08.002_bib0165","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2008.07.001","article-title":"Medical treatments for male and female pattern hair loss","volume":"59","author":"Rogers","year":"2008","journal-title":"J Am Acad Dematol"},{"key":"10.1016\/j.pharma.2021.08.002_bib0170","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/0974-2077.53093","article-title":"Finasteride\u2013its impact on sexual function and prostate cancer","volume":"2","author":"Anitha","year":"2009","journal-title":"J Cutan Aesthet Surg"},{"key":"10.1016\/j.pharma.2021.08.002_bib0175","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1067\/mjd.2001.117428","article-title":"Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss","volume":"45","author":"Whiting","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.pharma.2021.08.002_bib0180","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/bmj.317.7162.865","article-title":"Fortnighly review: male pattern androgenetic alopecia","volume":"317","author":"Sinclair","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.pharma.2021.08.002_bib0185","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1021\/bi00174a041","article-title":"17beta-(N-tert-Butylcarbamoyl)-4-aza-5alfa-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5\u03b1-reductase 1","volume":"33","author":"Tian","year":"1994","journal-title":"Biochemstry"},{"key":"10.1016\/j.pharma.2021.08.002_bib0190","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1527-3458.2006.00053.x","article-title":"A new look at the 5\u03b1-reductase inhibitor finasteride","volume":"12","author":"Finn","year":"2006","journal-title":"CNS Drug Reviews"},{"key":"10.1016\/j.pharma.2021.08.002_bib0195","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2217\/fon.10.149","article-title":"Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer","volume":"6","author":"Hulin-Curtis","year":"2010","journal-title":"Future Oncol"},{"key":"10.1016\/j.pharma.2021.08.002_bib0200","doi-asserted-by":"crossref","first-page":"842","DOI":"10.5414\/CP202119","article-title":"A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers","volume":"52","author":"Caserini","year":"2014","journal-title":"Int J Clin Pharmacol and Ther"},{"key":"10.1016\/j.pharma.2021.08.002_bib0205","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1007\/s11095-008-9642-z","article-title":"Dynamic dissolution testing to establish in vitro\/in vivo correlations for montelukast sodium, a poorly soluble drug","volume":"25","author":"Okumo","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharma.2021.08.002_bib0210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejpb.2008.10.019","article-title":"Computer simulations using GastroPlus\u2122 to justify a biowaiver for etoricoxib solid oral drug products","volume":"72","author":"Okumo","year":"2009","journal-title":"Eur J Pharm and Biopharm"},{"key":"10.1016\/j.pharma.2021.08.002_bib0215","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ejpb.2008.01.026","article-title":"Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption","volume":"69","author":"Wei","year":"2008","journal-title":"Eur J Pharm and Biopharm"},{"key":"10.1016\/j.pharma.2021.08.002_bib0220","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","article-title":"PBPK models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharma.2021.08.002_bib0225","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejpb.2015.12.004","article-title":"Disease specific modeling: simulation of the pharmacokinetics of meloxicam and ibuprofen in disease state vs. healthy conditions","volume":"100","author":"Almukainzi","year":"2016","journal-title":"Eur J Pharm and Biopharm"},{"key":"10.1016\/j.pharma.2021.08.002_bib0230","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1016\/j.xphs.2015.11.034","article-title":"Physiologically based absorption modeling to impact biopharmaceutics and formulation strategies in drug development- industry case studies","volume":"105","author":"Kesisoglou","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2021.08.002_bib0235","doi-asserted-by":"crossref","first-page":"242s","DOI":"10.18433\/jpps30227","article-title":"Application of in silico tools in clinical practice using ketoconazole as model drug","volume":"21","author":"Silva","year":"2018","journal-title":"J Pharmacy & Pharm Sci"},{"key":"10.1016\/j.pharma.2021.08.002_bib0240","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/pharmaceutics11050215","article-title":"In silico prediction of plasma concentrations of fluconazole capsules with different dissolution profiles and bioequivalence study using population simulation","volume":"11","author":"Duque","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharma.2021.08.002_bib0245","doi-asserted-by":"crossref","first-page":"150371","DOI":"10.1016\/j.ejps.2020.105371","article-title":"Schiff bases of 4-phenyl-2-aminothiazoles as hits to new antischistosomals: synthesis, in vitro, in vivo and in silico studies","volume":"150","author":"Amorim","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharma.2021.08.002_bib0250","series-title":"GastroPlus\u00ae version 9. 7 Manual","author":"Simulations Plus.","year":"2019"},{"key":"10.1016\/j.pharma.2021.08.002_bib0255","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2174\/15680266113139990033","article-title":"In silico ADMET prediction: recent advances, current challenges and future trends","volume":"13","author":"Cheng","year":"2013","journal-title":"Curr Top in Med Chem"},{"key":"10.1016\/j.pharma.2021.08.002_bib0260","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpba.2014.11.045","article-title":"Quality evaluation of the Finasteride polymorphic forms I and II in capsules","volume":"105","author":"Silva","year":"2015","journal-title":"J Pharm and Biom Ana"},{"key":"10.1016\/j.pharma.2021.08.002_bib0265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5414\/CP202467","article-title":"Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia","volume":"54","author":"Caserini","year":"2016","journal-title":"Int J Clin Pharm and Ther"},{"key":"10.1016\/j.pharma.2021.08.002_bib0270","series-title":"WebPlotDigitizer: Web Based Tool to Extract Data fromPlot, Images, andMaps. Version 4. 1","author":"Rohatgi","year":"2018"},{"key":"10.1016\/j.pharma.2021.08.002_bib0275","series-title":"Compound summary for CID 702, Ethanol","author":"Pubchem","year":"2018"},{"key":"10.1016\/j.pharma.2021.08.002_bib0280","series-title":"Product information: Item no. 14938\u2013Finasteride","author":"Cayman Chemical","year":"2015"},{"key":"10.1016\/j.pharma.2021.08.002_bib0285","first-page":"1","article-title":"Modelling the Absorption of Metformin with Patients Post Gastric Bypass Surgery","volume":"5","author":"Almukainzi","year":"2014","journal-title":"J Diab and Met"},{"key":"10.1016\/j.pharma.2021.08.002_bib0290","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40005-017-0307-y","article-title":"Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations","volume":"47","author":"Almukainzi","year":"2017","journal-title":"J Pharm Inv"},{"key":"10.1016\/j.pharma.2021.08.002_bib0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharma.2021.02.004","article-title":"Prediction of plasma concentrations using in silico modelling and simulation approach: case of acebutolol","author":"Bokri","year":"2021","journal-title":"Annales Pharmaceutiques Fran\u00e7aises"},{"key":"10.1016\/j.pharma.2021.08.002_bib0300","series-title":"Martindale: the complete drug reference.\u00a036. ed","first-page":"2188","author":"Sweetman","year":"2009"},{"key":"10.1016\/j.pharma.2021.08.002_bib0305","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1055\/s-0034-1376962","article-title":"Finasteride quantification in human plasma by high-performance liquid chromatography coupled to electrospray ionization tandem mass spectrometry. Application to a comparative pharmacokinetics study","volume":"65","author":"Moreno","year":"2015","journal-title":"Drug Res"},{"key":"10.1016\/j.pharma.2021.08.002_bib0310","first-page":"611","article-title":"A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women","volume":"17","author":"Lee","year":"2018","journal-title":"J Drugs Dermatol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345092100119X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345092100119X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:36:04Z","timestamp":1757720164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000345092100119X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S000345092100119X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2021.08.002","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical finasteride dose evaluation for treatment of androgenetic alopecia using computer simulations","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2021.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}